The newly issued shares consist exclusively of Class B stock, which carries one vote per share. Following this latest distribution, the company’s capital structure now comprises 74,344,689 listed Class B shares and 14,399,996 unlisted Class A shares. Because each Class A share commands ten votes, the total voting power within the Stockholm-based biopharma firm has reached 218,344,649.

This disclosure fulfills regulatory requirements under the Financial Instruments Trading Act. BioArctic, known for developing the Alzheimer’s treatment Leqembi alongside partner Eisai, continues to manage a pipeline focused on neurodegenerative diseases, including projects targeting Parkinson’s and ALS.